Bepridil
 | |
| Systematic (IUPAC) name | |
|---|---|
| N-benzyl-N-(3-isobutoxy-2-pyrrolidin-1-yl-propyl)aniline | |
| Clinical data | |
| Trade names | Vascor |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a699051 |
| |
| Oral | |
| Pharmacokinetic data | |
| Bioavailability | Well absorbed |
| Protein binding | 99% |
| Metabolism | Hepatic, CYP3A4-mediated |
| Half-life | 42 hours |
| Excretion | Renal |
| Identifiers | |
64706-54-3  | |
| C08EA02 | |
| PubChem | CID 2351 |
| IUPHAR ligand | 2337 |
| DrugBank |
DB01244 |
| ChemSpider |
2261 |
| UNII |
755BO701MA |
| ChEBI |
CHEBI:3061 |
| ChEMBL |
CHEMBL1008 |
| Chemical data | |
| Formula | C24H34N2O |
| 366.54 g/mol | |
|
SMILES
| |
| |
| (what is this?) (verify) | |
Bepridil (trade name Vascor) is a calcium channel blocker once used to treat angina. It is no longer sold in the United States.
It is nonselective.[1]
It has been discussed as a possible option in the treatment of atrial fibrillation.[2]
It has been implicated in causing ventricular arrhythmia (Torsades de pointes).
References
- ↑ Bezprozvanny I, Tsien RW (September 1995). "Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967)". Mol. Pharmacol. 48 (3): 540–9. PMID 7565636.
- ↑ Imai S, Saito F, Takase H et al. (May 2008). "Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm". Circ. J. 72 (5): 709–15. doi:10.1253/circj.72.709. PMID 18441448.